Fallopian Tube Cancers: Clinical Trials

9 trials for Fallopian Tube Cancers, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 not yet recruiting, 4 recruiting. 9 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 29Not yet recruiting 5, Recruiting 4
Phase 32Not yet recruiting 1, Recruiting 1
Phase 11Recruiting 1

Follow Fallopian Tube Cancers: new trials by email Literature Review of Fallopian Tube Cancers trials Research Report on Fallopian Tube Cancers

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer
Upfront cytoreductive surgery, Interval debulking surgery, Platinum-based chemotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancers
Phase 2 / Phase 3Not yet recruitingShanghai Gynecologic Oncology Group5342026-12-312026-11-12
Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
Trastuzumab Rezetecan (SHR-A1811), Bevacizumab, Platinum-based chemotherapy - Ovarian Cancer, Fallopian Tube Cancers
Phase 2Not yet recruitingPeking University Cancer Hospital & Institute532026-10-222026-10-01
Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin
Standard of Care + atorvastatin, Standard of Care (SOC) - Ovarian Cancer, Fallopian Tube Cancers
Phase 2Not yet recruitingUniversity of Colorado, Denver402026-09-012026-09-11
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
Aitua Combination Antibody, Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin (AUC 5) - High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers
Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences822026-07-232026-11-04
Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
Liposomal Irinotecan - Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital302026-05-302026-05-18
Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer
Benmelstobart in combination with Anlotinib and oral metronomic Cyclophosphamide - Ovarian Cancer, Fallopian Tube Cancers
Phase 2Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine402026-03-302026-03-24
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
TORL-1-23 and paclitaxel, TORL-1-23 and carboplatin, TORL-1-23, paclitaxel, and carboplatin - FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers
Phase 1 / Phase 2RecruitingTORL Biotherapeutics, LLC602025-12-102026-07-13
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
PARP inhibitor + Bevacizumab, PARP inhibitor - Ovarian Cancer, Fallopian Tube Cancers
Phase 2 / Phase 3RecruitingN.N. Alexandrov National Cancer Centre1202025-07-012026-03-16
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Mirvetuximab Soravtansine - Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer
Phase 2RecruitingAbbVie1102025-05-282026-05-26

Narrower conditions

Fallopian Tube Neoplasms (9)  ·  Ovarian Neoplasms (5)  ·  Carcinoma, Ovarian Epithelial (3)

Broader conditions

Adnexal Diseases (9)  ·  Fallopian Tube Diseases (9)  ·  Female Urogenital Diseases (9)  ·  Female Urogenital Diseases and Pregnancy Complications (9)  ·  Genital Diseases (9)  ·  Genital Diseases, Female (9)  ·  Genital Neoplasms, Female (9)  ·  Neoplasms (9)  ·  Neoplasms by Site (9)  ·  Urogenital Diseases (9)  ·  Urogenital Neoplasms (9)  ·  Endocrine Gland Neoplasms (6)  ·  Endocrine System Diseases (6)  ·  Gonadal Disorders (6)  ·  Ovarian Diseases (6)

Interventions

Bevacizumab (2)  ·  Carboplatin (2)  ·  Platinum Compounds (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  Albumin-Bound Paclitaxel (1)  ·  Atorvastatin (1)  ·  Paclitaxel (1)  ·  Poly(ADP-ribose) Polymerase Inhibitors (1)  ·  Standard of Care (1)  ·  anlotinib (1)  ·  irinotecan sucrosofate (1)  ·  mirvetuximab soravtansine (1)

Sponsors

AbbVie (1)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)  ·  N.N. Alexandrov National Cancer Centre (1)  ·  Peking University Cancer Hospital & Institute (1)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (1)  ·  Shanghai Gynecologic Oncology Group (1)  ·  TORL Biotherapeutics, LLC (1)  ·  Tianjin Medical University Cancer Institute and Hospital (1)  ·  University of Colorado, Denver (1)

Countries

China (3)  ·  United States (3)  ·  Australia (1)  ·  Belarus (1)  ·  Belgium (1)  ·  France (1)  ·  Poland (1)  ·  South Korea (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Nicole Marjon, MD, PhD (1)  ·  Ning Li, MD (1)